M&A Deal Summary |
|
---|---|
Date | 2013-09-09 |
Target | Lucozade Ribena Suntory |
Sector | Beverages |
Buyer(s) | Suntory Beverage & Food |
Sellers(s) | GSK |
Deal Type | Divestiture |
Deal Value | 1.4B GBP |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2009 |
Sector | Beverages |
Revenue | 1.59T JPY (2023) |
Suntory Beverage & Food is a Japanese whiskey and soft-drinks company. Suntory Beverage & Food was founded in 2009 and is based in Tokyo, Japan.
DEAL STATS | # |
---|---|
Overall | 7 of 9 |
Sector (Beverages) | 5 of 7 |
Type (Divestiture) | 3 of 3 |
Country (United Kingdom) | 1 of 1 |
Year (2013) | 1 of 1 |
Size (of disclosed) | 2 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2009-11-13 |
Orangina
Amsterdam, Netherlands Orangina is a fruit-based soft drinks business that markets, bottles, distributes and franchises a number of carbonated and other soft drinks. Orangina was founded in 1936 and is based in Amsterdam, Netherlands. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-01-13 |
Beam
Deerfield, Illinois, United States Beam is a global spirits company. The Company's brands include Jim Beam Bourbon, Maker's Mark Bourbon, Sauza Tequila, Pinnacle Vodka, Canadian Club Whisky, Courvoisier Cognac, Teacher's Scotch Whisky, Skinnygirl Cocktails, Cruzan Rum, Hornitos Tequila, Knob Creek Bourbon, Laphroaig Scotch Whisky, Kilbeggan Irish Whiskey, Larios Gin, Whisky DYC and DeKuyper Cordials. Beam dates back to 1904 and is based in Deerfield, Illinois. |
Buy | $16.0B |
Category | Company |
---|---|
Founded | 1715 |
Sector | Life Science |
Employees | 70,212 |
Revenue | 30.3B GBP (2023) |
GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.
DEAL STATS | # |
---|---|
Overall | 10 of 24 |
Sector (Beverages) | 1 of 1 |
Type (Divestiture) | 10 of 23 |
Country (United Kingdom) | 3 of 13 |
Year (2013) | 1 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-05-29 |
Okairos AG
Basel, Switzerland Okairos - is a non-listed clinical-stage biopharmaceutical company, developing genetic vaccines for major infectious diseases - including malaria, hepatitis C, HIV, respiratory syncytial virus and cancer - using a novel proprietary technology. The company is also pursuing therapeutic vaccines to treat cancer. |
Buy | €250M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-09-30 |
GSK s Arixtra Fraxiparine brands
United Kingdom Arixtra and Fraxiparine/Fraxodi are made at a sterile site and the ability to manufacture steriles is globally recognised as a specialist activity resulting in limited possible competition. This is a factor further underlined by the increased complexity of the manufacturing process of Fraxiparine/Fraxodi due to the biological nature of the active pharmaceutical ingredients (“API”) used in their production. |
Sell | £700M |